Skip to main content
Yantai Zhenghai Bio-Tech Co., Ltd. logo

Yantai Zhenghai Bio-Tech Co., Ltd. — Investor Relations & Filings

Ticker · 300653 ISIN · CNE100002NZ1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 970 across all filing types
Latest filing 2023-07-31 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300653

About Yantai Zhenghai Bio-Tech Co., Ltd.

https://www.zhbio.com

Yantai Zhenghai Bio-Tech Co., Ltd. specializes in the research, development, production, and sale of regenerative medicine materials. The company focuses on tissue engineering and biomaterials to provide solutions for clinical repair and functional reconstruction. Its core product portfolio includes the Heal-All oral repair membrane, absorbable hard cerebral (spinal) membrane patches, and skin repair membranes. These products are widely utilized in stomatology, neurosurgery, and orthopedics. The company leverages advanced processing technologies to ensure biocompatibility and safety in its medical devices. By integrating research with clinical needs, it develops innovative bone repair materials and other biological scaffolds designed to facilitate natural tissue regeneration.

Recent filings

Filing Released Lang Actions
独立董事关于相关事项的独立意见
Audit Report / Information Classification · 95% confidence The document is titled 'Independent Directors' Opinions on Relevant Matters' and discusses the independent directors' review and opinions on the company's external guarantees and related party fund occupation for the half-year period ending June 30, 2023. It references regulatory guidelines and the company's internal rules. The document is relatively short (871 characters) and contains independent directors' opinions rather than full financial statements or comprehensive management discussion. It is not an annual or interim report, nor an earnings release. It is a specialized report by independent directors on specific governance and financial oversight matters, which aligns with the category of Audit Report / Information (AR), as it involves audit-related opinions and compliance with regulatory requirements. Therefore, the classification is AR with high confidence. H1 2023
2023-07-31 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is titled as a '监事会决议公告' which translates to 'Supervisory Board Resolution Announcement'. It details the meeting of the supervisory board held on July 30, 2023, and specifically discusses the review and approval of the company's 2023 semi-annual report and its summary. The document states that the supervisory board has reviewed and approved the report, confirming its accuracy and compliance with regulations. However, the document itself does not contain the full semi-annual report or detailed financial data; it only announces the resolution and points to the full report being available on the official disclosure website. The document length is short (904 characters), and it serves as an announcement of the supervisory board's resolution regarding the semi-annual report rather than the report itself. According to the 'MENU VS MEAL' rule, such a document is classified as a Regulatory Filing (RNS) because it is an announcement related to a report, not the report itself.
2023-07-31 Chinese
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "烟台正海生物科技股份有限公司2023 年半年度报告全文" which translates to "Yantai Zhenghai Bio-Tech Co., Ltd. 2023 Semi-Annual Report Full Text." It is dated August 1, 2023, and covers the reporting period from January 1, 2023, to June 30, 2023. The content includes detailed financial data such as revenue, net profit, earnings per share, and asset information. It also contains management discussion and analysis, company overview, risk factors, product information, and operational details. The length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The document explicitly states it is a "半年度报告" (semi-annual report), which corresponds to an Interim / Quarterly Report. Therefore, the document is classified as an Interim / Quarterly Report (IR). H1 2023
2023-07-31 Chinese
2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023 半年度报告摘要' which translates to '2023 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and asset information for the half-year period. It also discusses business operations, product sales, R&D progress, internal controls, and management initiatives during the reporting period. The presence of comprehensive financial metrics and operational commentary indicates this is a substantive interim financial report rather than a brief announcement or summary. The document length is 4594 characters, which is sufficient for a summary but given the detailed financial and operational data, it aligns with an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K) as it covers only half-year data. There is no indication that this is merely an announcement or certification, so it is not RPA or RNS. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2023
2023-07-31 Chinese
上市公司2023年半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 95% confidence The document is a summary table detailing non-operating fund occupation and other related party fund transactions for the half-year period of 2023. It includes financial figures such as beginning balances, cumulative amounts, interest, repayments, and ending balances. The document is relatively short (998 characters) and contains specific financial data for a half-year period. This indicates it is a financial report for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report (IR). It is not an announcement or a certification but contains substantive financial data and analysis for the half-year period. H1 2023
2023-07-31 Chinese
关于公司获得医疗器械注册申请《受理通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1144 characters) from a company about receiving acceptance of a medical device registration application from a regulatory authority (国家药品监督管理局 - National Medical Products Administration). It describes the product, the current approval stage (application accepted), and the next steps in the approval process. It also includes a risk warning about the uncertain impact on business. There are no financial statements, no detailed financial data, no earnings or management discussion, and no mention of shareholder votes or meetings. The document is clearly an announcement of a regulatory milestone rather than a full report or detailed filing. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2023-07-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.